SMART (Single Maintenance And Reliever Therapy) is a GINA-recommended asthma management strategy using a single inhaler containing a combination of budesonide (inhaled corticosteroid — ICS) and formoterol (rapid-onset, long-acting beta-2 agonist — LABA) for BOTH daily maintenance AND as-needed rescue therapy. This approach capitalizes on formoterol's unique pharmacological profile: unlike salmeterol (which has slow onset), formoterol has rapid bronchodilator onset (1-3 minutes) comparable to albuterol, combined with 12-hour duration of action. When the patient uses the combination inhaler for rescue, they simultaneously receive an anti-inflammatory dose of ICS with every rescue puff, addressing the airway inflammation that drives bronchoconstriction. This eliminates the dangerous pattern of SABA overuse without ICS during exacerbations (which provides bronchodilation without treating underlying inflammation). Evidence from the SYGMA trials and GINA 2019+ guidelines demonstrates that SMART reduces severe exacerbations by 30-50% compared to fixed-dose ICS-LABA with SABA rescue, reduces total ICS exposure (patients titrate their own anti-inflammatory therapy based on symptoms), and improves adherence (single inhaler simplifies the regimen). The SMART approach is recommended for GINA Steps 3-5 (moderate-severe persistent asthma). For mild asthma (GINA Steps...